Research

Hormonal

GIP receptor (GIPR) antagonism enhances the weight-loss efficacy of GLP-1 receptor agonists by removing an inhibitory tone on central nervous system (CNS) satiety circuits, specifically within hindbrain GABAergic neurons.

If you are using a GLP-1 medication (like semaglutide or liraglutide) and experiencing significant side effects like nausea without sufficient weight loss, newer therapies that block the GIP receptor (antagonism) while activating GLP-1 may be more effective and tolerable. This works by removing a natural 'brake' on your brain's satiety signals, allowing the medication to work more efficiently.

GoodSupportsHIGH confidence
Reducing this inhibitory tone, potentially through naturally occurring human GIPR variants with reduced signaling properties, or via pharmacological GIPR antagonism, could enhance the activity of anorectic GLP-1R signaling pathways, thereby increasing the sensitivity to and effectiveness of endogenous GLP-1 or pharmacological GLP-1R agonism.
Jonathan E. Campbell et al. · Diabetes · 2025

Why this rating

Supported by multiple preclinical mouse studies, human genetics (loss-of-function variants), and emerging clinical data on bispecific antibodies.

Source

Therapeutic Targeting of the GIP Receptor—Revisiting the Controversies

Jonathan E. Campbell et al. · Diabetes · 2025

DOI 10.2337/db25-0393

narrative_reviewCited 5×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →